进展期胃癌术中行区域性缓释化疗的安全性评价  

Advanced gastric cancer intraoperative regional safety evaluation of sustained-release chemotherapy

作　　者：何行昌[1] 

机构地区：[1]河南省商丘市第一人民医院普外科,476100

出　　处：《中国实用医药》2011年第27期32-33,共2页China Practical Medicine

摘　　要：目的探讨进展期胃癌术中腹腔内行区域性植入5-氟尿嘧啶缓释化疗的临床疗效及用药安全进行分析评价。方法将60例进展期胃癌患者均进行手术根治切除术后并随机分为两组,治疗组:30例患者给予术中行区域性缓释化疗;对照组30例患者与治疗组患者术后均进行常规全身化疗,并对其两组患者治疗后临床疗效进行疗效评价及安全性评价。结果疗效判定治疗组:完全缓解8例占26.7%、部分缓解11例占36.7%、疾病稳定7例占23.3%、疾病进展4例占13.3%。对照组:完全缓解5例占1.7%、部分缓解9例占30.0%、疾病稳定11例占36.7%、疾病进展5例占16.7%。两组患者在治疗后腹腔相关并发症与化疗毒副作用无显著差异。结论进展期胃癌术中腹腔内行区域性植入5-氟尿嘧啶缓释化疗,患者耐受性良好,用药后临床疗效增加而未见明显的全身、局部不良反应。Objective To discuss advanced gastric cancer implanted in the abdominal cavity of region- al experts 5-Fluorouracil chemotherapy efficacy and sustained-release drug safety analysis and evalua- tion. Methods 60 cases of advanced gastric cancer patients underwent radical surgical resection were randomly divided into treatment greups：30 patients were treated with intraoperative regional slow-release chemotherapy, control group of 30 patients with treatment group patientsare routine chemotherapy, and two groups of patients after their clinical efficacy evaluation and safety evaluation. Results Determine the efficacy of the treatment groups：complete remission in 8 cases accounted for 26.7 %, partial response 11 cases accounted for 36. 7%, seven cases of stable disease 23.3%, disease progression was four cases （ 13.3% ）. Control group ：5 cases were （ 1.7% ） complete remission, partial remission in 9 cases accounted for 30.0%, stable disease 11 cases accounted for 36. 7%, disease progression, five cases of 16. 7%. Two groups of patients after abdominal-related complications in the treatment of chemotherapy side effects with no significant difference. Conclusion Advanced gastric cancer surgery in the abdominal cavity implantation of regional experts 5-Fluorouracil sustainedrelease chemotherapy, the patient is well tolerated, clinical efficacy after treatment no significant increase in systemic and local adverse reactions.

关 键 词：进展期胃癌 区域缓释化疗 5-氟尿嘧啶缓释剂 疗效评价 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]